Systolic Heart failure treatment with the If inhibitor ivabradine Trial Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study Effect of ivabradine on outcomes in patients with chronic heart failure and HR 75 bpm Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Aim To assess the effect of ivabradine on outcomes in heart failure patients on recommended background therapies with heart rates ≥75 bpm in the SHIFT trial Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Baseline characteristics Ivabradine Placebo n=2052 n=2098 Mean age, years 60 60 Male, % 77 77 BMI, kg/m2 28 28 Mean HF duration, years 3.4 3.4 HF ischemic cause, % 66 65 NYHA class III, % 50 51 NYHA class IV, % 2 2 Mean LVEF, % 28.7 28.5 Mean HR, bpm 84.3 84.6 Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Baseline background treatment Ivabradine Placebo n=2052 n=2098 87 88 At least half target dose 55 56 At target dose 26 26 ACE inhibitors/ARBs, % 90 90 Diuretics (excludes AAs), % 85 83 Aldosterone antagonists, % 63 61 β-Blockers, % Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Effect of ivabradine on primary outcome CV death or hospitalization for HF Patients with primary composite end point (%) Hazard ratio=0.76 P<0.0001 40 Placebo 30 Ivabradine 20 10 0 0 6 12 18 24 30 Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Effect of ivabradine on cardiovascular death Hazard ratio=0.83 30 Patients with cardiovascular death (%) P=0.0166 Placebo 20 Ivabradine 10 0 0 6 12 18 24 30 Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Effect of ivabradine on hospital admission for worsening heart failure Hazard ratio=0.70 Patients with cardiovascular death (%) 30 Placebo P<0.0001 20 Ivabradine 10 0 0 6 12 18 24 30 Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Effect of ivabradine on major outcomes P Hazard ratio 95% CI Primary composite end point 0.76 0.68-0.85 <0.0001 Cardiovascular mortality 0.83 0.71-0.97 0.0166 Hospitalization for worsening HF 0.70 0.61-0.80 <0.0001 Death from HF 0.61 0.46-0.81 0.0006 All-cause mortality 0.83 0.72-0.96 0.0109 All-cause hospitalization 0.82 0.75-0.90 <0.0001 Any cardiovascular hospitalization 0.79 0.71-0.88 <0.0001 0.20 0.40 0.60 0.80 Favors ivabradine Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 1.00 1.20 Favors placebo www.shift-study.com Effect of ivabradine on outcomes according to HR achieved at 28 days Patients with primary composite end point (%) 40 75 bpm 30 70 to <75 bpm 65 to <70 bpm 60 to <65 bpm 20 <60 bpm 10 0 0 Day 28 6 12 18 24 Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Effect of ivabradine on outcomes according to magnitude of HR reduction Patients with primary composite end point (%) 40 0 bpm -10 to <0 bpm 30 < -10 bpm 20 10 0 0 Day 28 6 12 18 24 Time (months) Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com Conclusions In HF in sinus rhythm with HR ≥75 bpm heart rate reduction with ivabradine improves outcomes, including all-cause death and cardiovascular death reduces Ivabradine-associated risk reductions are related to both HR achieved and magnitude of HR reduction Patients achieving <60 bpm or with >10 bpm reduction have the best prognosis Böhm M, Borer J, Ford I, et al. Clin Res Cardiol. 2013;102(1):11-22 www.shift-study.com
© Copyright 2024